Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q1 EPS of ($0.35), $0.30 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $32.98 million versus the consensus estimate of $7.88 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.